{"id":"W4410264696","doi":"10.1016/j.jhep.2025.04.025","title":"Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial","year":2025,"lang":"en","type":"article","venue":"Journal of Hepatology","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; University of Alberta; William Osler Health System","funders":"Ipsen; Astellas Pharma; NGM Biopharmaceuticals; Ipsen Biopharmaceuticals; Gilead Sciences; Novo Nordisk; Eisai; Sanofi; Dr. Falk Pharma; GlaxoSmithKline; AstraZeneca","keywords":"Primary sclerosing cholangitis; Randomized controlled trial; Medicine; Internal medicine; Gastroenterology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001566273,0.0001019929,0.00167388,0.0002256731,0.00008398212,0.000008644866,0.0001035339,0.0000809283,0.0000407448],"category_scores_gemma":[0.001185282,0.00005611614,0.0004059413,0.0001403898,0.0002004646,0.00008486963,0.00005805491,0.0003309217,2.993121e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004749568,"about_ca_system_score_gemma":0.0003855303,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003210766,"about_ca_topic_score_gemma":0.000002129545,"domain_scores_codex":[0.9979873,0.0006054493,0.001046202,0.00007878479,0.0001364675,0.0001457697],"domain_scores_gemma":[0.9978043,0.001374068,0.0005015442,0.0001514666,0.0001116976,0.00005691695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9873081,0.001100864,0.004527216,0.00004919159,0.0005911405,0.00003302135,0.0002193684,0.000001845869,0.001071103,0.0001858171,0.0001247645,0.004787544],"study_design_scores_gemma":[0.9804718,0.00120752,0.01607176,0.000276565,0.00104632,0.0001344582,0.00006035419,0.000118188,0.0001869694,0.0001545076,0.0002295543,0.00004203741],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868267,0.007787111,0.00009455198,0.002505416,0.0003813946,0.001137814,0.000002984735,0.000003562752,0.001260468],"genre_scores_gemma":[0.9978923,0.001286543,0.0001002398,0.0005285933,0.00009504835,0.000006869901,0.000002171545,0.000005354233,0.00008291691],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01154454,"threshold_uncertainty_score":0.228835,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01007799212067643,"score_gpt":0.2877894008974864,"score_spread":0.2777114087768099,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}